CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells.

Immunotherapeutic strategies to stimulate anti-tumor immunity are promising approaches for cancer treatment. A major barrier to their success is the immunosuppressive microenvironment of tumors, which inhibits the functions of endogenous dendritic cells (DCs) that are necessary for the generation of...

Full description

Bibliographic Details
Main Authors: Alice W Yewdall, Scott B Drutman, Felecia Jinwala, Keith S Bahjat, Nina Bhardwaj
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2010-06-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC2886840?pdf=render
_version_ 1818336393646047232
author Alice W Yewdall
Scott B Drutman
Felecia Jinwala
Keith S Bahjat
Nina Bhardwaj
author_facet Alice W Yewdall
Scott B Drutman
Felecia Jinwala
Keith S Bahjat
Nina Bhardwaj
author_sort Alice W Yewdall
collection DOAJ
description Immunotherapeutic strategies to stimulate anti-tumor immunity are promising approaches for cancer treatment. A major barrier to their success is the immunosuppressive microenvironment of tumors, which inhibits the functions of endogenous dendritic cells (DCs) that are necessary for the generation of anti-tumor CD8+ T cells. To overcome this problem, autologous DCs are generated ex vivo, loaded with tumor antigens, and activated in this non-suppressive environment before administration to patients. However, DC-based vaccines rarely induce tumor regression.We examined the fate and function of these DCs following their injection using murine models, in order to better understand their interaction with the host immune system. Contrary to previous assumptions, we show that DC vaccines have an insignificant role in directly priming CD8+ T cells, but instead function primarily as vehicles for transferring antigens to endogenous antigen presenting cells, which are responsible for the subsequent activation of T cells.This reliance on endogenous immune cells may explain the limited success of current DC vaccines to treat cancer and offers new insight into how these therapies can be improved. Future approaches should focus on creating DC vaccines that are more effective at directly priming T cells, or abrogating the tumor induced suppression of endogenous DCs.
first_indexed 2024-12-13T14:38:37Z
format Article
id doaj.art-46912c75a9b54ebc874d3c405e09a90d
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-13T14:38:37Z
publishDate 2010-06-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-46912c75a9b54ebc874d3c405e09a90d2022-12-21T23:41:39ZengPublic Library of Science (PLoS)PLoS ONE1932-62032010-06-0156e1114410.1371/journal.pone.0011144CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells.Alice W YewdallScott B DrutmanFelecia JinwalaKeith S BahjatNina BhardwajImmunotherapeutic strategies to stimulate anti-tumor immunity are promising approaches for cancer treatment. A major barrier to their success is the immunosuppressive microenvironment of tumors, which inhibits the functions of endogenous dendritic cells (DCs) that are necessary for the generation of anti-tumor CD8+ T cells. To overcome this problem, autologous DCs are generated ex vivo, loaded with tumor antigens, and activated in this non-suppressive environment before administration to patients. However, DC-based vaccines rarely induce tumor regression.We examined the fate and function of these DCs following their injection using murine models, in order to better understand their interaction with the host immune system. Contrary to previous assumptions, we show that DC vaccines have an insignificant role in directly priming CD8+ T cells, but instead function primarily as vehicles for transferring antigens to endogenous antigen presenting cells, which are responsible for the subsequent activation of T cells.This reliance on endogenous immune cells may explain the limited success of current DC vaccines to treat cancer and offers new insight into how these therapies can be improved. Future approaches should focus on creating DC vaccines that are more effective at directly priming T cells, or abrogating the tumor induced suppression of endogenous DCs.http://europepmc.org/articles/PMC2886840?pdf=render
spellingShingle Alice W Yewdall
Scott B Drutman
Felecia Jinwala
Keith S Bahjat
Nina Bhardwaj
CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells.
PLoS ONE
title CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells.
title_full CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells.
title_fullStr CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells.
title_full_unstemmed CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells.
title_short CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells.
title_sort cd8 t cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells
url http://europepmc.org/articles/PMC2886840?pdf=render
work_keys_str_mv AT alicewyewdall cd8tcellprimingbydendriticcellvaccinesrequiresantigentransfertoendogenousantigenpresentingcells
AT scottbdrutman cd8tcellprimingbydendriticcellvaccinesrequiresantigentransfertoendogenousantigenpresentingcells
AT feleciajinwala cd8tcellprimingbydendriticcellvaccinesrequiresantigentransfertoendogenousantigenpresentingcells
AT keithsbahjat cd8tcellprimingbydendriticcellvaccinesrequiresantigentransfertoendogenousantigenpresentingcells
AT ninabhardwaj cd8tcellprimingbydendriticcellvaccinesrequiresantigentransfertoendogenousantigenpresentingcells